University of Cambridge > > Cambridge Network events > Cambridge Network event: Biologics in Cambridge - from Cambridge Antibody Technology to MedImmune and Astra-Zeneca

Cambridge Network event: Biologics in Cambridge - from Cambridge Antibody Technology to MedImmune and Astra-Zeneca

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Louise Rushworth.

We’re delighted to welcome Jon Green, VP Business Operations, and Dr Paul Varley, VP Science and Collaborations, Biopharmaceutical Development, from MedImmune as our speakers for January’s event. Jon and Paul will be joined by Harriet Fear, CEO of One Nucleus.

MedImmune has built on the local legacy of Cambridge Antibody Technology, leaders in antibody technology who discovered three marketed medicines: Humira® (adalimumab), an important anti-TNF antibody now marketed by Abbott Laboratories.1 , Benlysta® (belimumab), a first new treatment for active systemic lupus erythematosus in decades, now marketed by Human Genome Sciences and GlaxoSmithKline2 and ABthrax® (raxibacumab) anti-anthrax antibody marketed by Human Genome Sciences and GlaxoSmithKline.

Committed to Cambridge, and firmly established in local business networks and community activities, MedImmune is proud of its strong and enduring collaborative links with academics, researchers, charities, foundations and neighbouring companies. By 2016, MedImmune will be joined in Cambridge by AstraZeneca’s new UK-based global research and development centre and corporate headquarters will be located at the Cambridge Biomedical Campus, bringing together AstraZeneca’s small molecule and MedImmune’s biologics research and development. The decision to locate AstraZeneca’s global R&D centre and corporate headquarters in Cambridge underscores the UK’s international importance as a location for biopharmaceutical research and development. Jon Green and Paul Varley will be talking about the past, present and future of MedImmune – Astra-Zeneca and its work here in Cambridge. 

Joining the MedImmune speakers will be Harriet Fear, CEO of One Nucleus, an international membership organisation for life science and healthcare companies, based in Cambridge and London. A not-for-profit company, it is the largest of its kind in Europe by some way with over 470 members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

To book please click on this link –

Timings: The talk will last for about 30-40 minutes, followed by Q&A . There will be a light refreshments and an opportunity to network after the event, which we estimate will end around 8.30pm.

This talk is part of the Cambridge Network events series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2023, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity